Domenica Lorusso Selected Research

niraparib

3/2022	Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
10/2021	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
11/2020	First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
12/2019	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
6/2017	[Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.]
12/2016	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Domenica Lorusso Research Topics

Disease

92	Ovarian Neoplasms (Ovarian Cancer) 12/2022 - 01/2002
69	Neoplasms (Cancer) 04/2022 - 04/2006
31	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022 - 04/2006
19	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 01/2011
16	Carcinoma (Carcinomatosis) 01/2022 - 11/2006
12	Ovarian Epithelial Carcinoma 01/2022 - 10/2010
10	Disease Progression 10/2022 - 06/2015
10	Vomiting 05/2020 - 02/2013
9	Nausea 11/2021 - 02/2013
9	Sarcoma (Soft Tissue Sarcoma) 11/2020 - 12/2009
8	Leiomyosarcoma 04/2022 - 01/2015
7	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2011
6	Neutropenia 12/2022 - 02/2008
6	Anemia 12/2022 - 11/2006
5	Fatigue 11/2021 - 05/2015
4	Adenocarcinoma 01/2021 - 05/2014
4	Hypertension (High Blood Pressure) 01/2021 - 05/2015
4	Infections 01/2019 - 03/2017
4	Breast Neoplasms (Breast Cancer) 11/2016 - 12/2009
2	Rare Diseases (Rare Disease) 04/2022 - 01/2018
2	Fallopian Tube Neoplasms 12/2021 - 12/2021
2	Lung Neoplasms (Lung Cancer) 12/2020 - 02/2013
2	Melanoma (Melanoma, Malignant) 12/2020 - 11/2019
2	Granulosa Cell Tumor 12/2020 - 02/2015
2	Alopecia (Baldness) 01/2020 - 09/2011
2	Asthenia 01/2020 - 11/2019
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 10/2019 - 01/2011
2	Papillomavirus Infections 09/2018 - 03/2017
2	Smooth Muscle Tumor 01/2018 - 05/2016
2	Myoma 01/2017 - 07/2016

Drug/Important Bio-Agent (IBA)

47	PlatinumIBA 12/2022 - 08/2005
25	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 08/2005
19	Bevacizumab (Avastin)FDA Link 03/2022 - 07/2013
17	Poly(ADP-ribose) Polymerase InhibitorsIBA 03/2022 - 06/2017
17	Carboplatin (JM8)FDA LinkGeneric 06/2021 - 06/2008
15	liposomal doxorubicin (Doxil)FDA Link 11/2021 - 01/2002
14	rucaparibIBA 12/2022 - 10/2017
11	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 03/2022 - 10/2016
10	1-dodecylpyridoxal (PLD)IBA 11/2021 - 08/2005
9	Immune Checkpoint InhibitorsIBA 03/2022 - 11/2019
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2011
9	Pharmaceutical PreparationsIBA 01/2021 - 10/2010
8	olaparibIBA 03/2022 - 01/2018
8	Cisplatin (Platino)FDA LinkGeneric 10/2020 - 06/2010
6	niraparibIBA 03/2022 - 12/2016
6	TrabectedinIBA 01/2021 - 09/2013
6	Gemcitabine FDA Link 01/2021 - 01/2002
5	pembrolizumabIBA 01/2022 - 01/2021
4	lenvatinibIBA 01/2022 - 01/2021
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 10/2010
4	Poly Adenosine Diphosphate RiboseIBA 01/2022 - 01/2021
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 10/2016
4	Angiogenesis InhibitorsIBA 06/2018 - 05/2015
3	Biological ProductsIBA 04/2022 - 01/2021
3	Monoclonal AntibodiesIBA 12/2021 - 07/2013
3	AntigensIBA 02/2021 - 07/2017
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 05/2015
3	AntiemeticsIBA 01/2020 - 03/2017
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2016
2	PM 01183IBA 01/2022 - 11/2021
2	dostarlimabIBA 01/2022 - 10/2021
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 06/2015
2	NivolumabIBA 01/2022 - 12/2021
2	B7-H1 AntigenIBA 11/2021 - 12/2020
2	Topotecan (Hycamtin)FDA LinkGeneric 11/2021 - 06/2010
2	oregovomabIBA 02/2021 - 01/2020
2	Alanine Transaminase (SGPT)IBA 01/2021 - 05/2015
2	Hormones (Hormone)IBA 11/2020 - 01/2019
2	Hemoglobins (Hemoglobin)IBA 01/2020 - 11/2019
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 12/2019 - 12/2016
2	Adenosine Diphosphate (ADP)IBA 12/2019 - 12/2016
2	taxaneIBA 12/2019 - 11/2011
2	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2019 - 02/2018
2	Messenger RNA (mRNA)IBA 01/2019 - 01/2016
2	pertuzumabIBA 01/2019 - 01/2016
2	pazopanib FDA Link 08/2017 - 05/2015
2	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2017 - 01/2015
2	Ifosfamide FDA LinkGeneric 11/2016 - 09/2014
1	LigandsIBA 10/2022
1	cemiplimabIBA 10/2022

Therapy/Procedure

59	Drug Therapy (Chemotherapy) 12/2022 - 06/2008
45	Therapeutics 04/2022 - 11/2006
12	Radiotherapy 01/2022 - 08/2009
12	Neoadjuvant Therapy 06/2019 - 05/2014
10	Immunotherapy 03/2022 - 11/2019
10	Cytoreduction Surgical Procedures 12/2021 - 08/2006
10	Hysterectomy 04/2020 - 01/2015
7	Lymph Node Excision (Lymph Node Dissection) 11/2020 - 11/2013
7	Morcellation 11/2020 - 02/2016
5	Minimally Invasive Surgical Procedures 11/2019 - 05/2017
3	Blood Transfusion (Blood Transfusions) 02/2017 - 05/2016
3	Salvage Therapy 09/2013 - 08/2005
2	Precision Medicine 04/2021 - 03/2021
2	Palliative Care (Palliative Therapy) 02/2021 - 01/2021
2	Salpingo-oophorectomy 11/2020 - 10/2016
2	Hyperthermic Intraperitoneal Chemotherapy 01/2020 - 11/2017
2	Lasers (Laser) 03/2019 - 01/2018
2	Aftercare (After-Treatment) 01/2019 - 03/2017
2	Chemoradiotherapy 01/2018 - 11/2006
2	Adjuvant Chemotherapy 11/2016 - 01/2015